Biomarkers and Alzheimer's disease Research
Areas of interest are:
1) Genes within biological pathways relevant to AD pathogenesis and their association with known cerebrospinal fluid biomarkers, such as Abeta and Tau. So far we have identified multiple genetic variants associated with cerebrospinal fluid apoE, APP, Abeta or tau levels. Next, using statistical methods and bioinformatics we will investigate possible combinatorial associations between these variants in AD.
2) Assocations between non-coding RNA levels and AD. So far, in a small pilot study, we identified one plasma microRNA that was uniquely present in patients with Alzheimer’s disease. Next, we will measure microRNA levels in another larger cohort and study the functional impact of AD specific microRNA on gene regulation.
3) Disruption of normal function by genetic variants. In this work our lab produces libraries of genetic variants. These libraries are used to study how these variants might disrupt normal function or how certain small molecules might correct this disruption of function.
There is no treatment that stops cognitive decline in Alzheimer’s disease or other dementias. Biomarker research is critical for the development of treatments that will prevent or cure Alzheimer’s disease.
Our research is focused on identifying and evaluating the functional impact of genetic and epigenetic markers of Alzheimer’s disease.